Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kriangkrai Tawinprai has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Gaidganok Sornsamdang

    Chulabhorn Hospital, Chulabhorn Royal Academy

    7 shared publications
  • Thachanun Porntharukchareon

    Chulabhorn Royal Academy

    6 shared publications
  • Kamonwan Soonklang

    Center of Learning and Research in Celebration of HRH Princess Chulabhorn’s 60th Birthday Anniversary, Chulabhorn Royal Academy, Bangkok, Thailand

    5 shared publications
  • Kasiruck Wittayasak

    Center of Learning and Research in Celebration of HRH Princess Chulabhorn’s 60th Birthday Anniversary, Chulabhorn Royal Academy, Bangkok, Thailand

    5 shared publications
  • Nithi Mahanonda

    Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand

    5 shared publications
  • Taweegrit Siripongboonsitti

    Chulabhorn Hospital, Chulabhorn Royal Academy

    5 shared publications

Latest Publications

  • Effect of Corticosteroid on Immunogenicity of SARS-CoV-2 Vaccines in Patients With Solid Cancer

    by Chayanee Samdaengpan, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej, Jomtana Siripaibun, Chumut Phanthunane, Walaipan Tantiyavarong, Wisut Lamlertthon, Teerapat Ungtrakul, Kriangkrai Tawinprai, et al.

    PURPOSE: Corticosteroids are known to diminish immune response ability, which is generally used in routine premedication for chemotherapy. The intersecting of timeframe between the corticosteroid's duration of action and peak COVID-19 vaccine efficacy could impair vaccine immunogenicity. Thus, inquiring about corticosteroids affecting the efficacy of vaccines to promote effective immunity in this population is needed. METHODS: This was a prospective longitudinal observational cohort study that enrolled patients with solid cancer classified into dexamethasone- and nondexamethasone-receiving groups. All participants were immunized with two doses of ChAdOx1 nCoV-19 or CoronaVac vaccines. This study's purpose was to compare corticosteroid's effect on immunogenicity responses to the SARS-CoV-2 S protein in patients with cancer after two doses of COVID-19 vaccine in the dexamethasone and nondexamethasone group. Secondary outcomes included the postimmunization anti–spike (S) immunoglobin G (IgG) seroconversion rate, the association of corticosteroid dosage, time duration, and immunogenicity level. RESULTS: Among the 161 enrolled patients with solid cancer, 71 and 90 were in the dexamethasone and nondexamethasone groups, respectively. The median anti–S IgG titer after COVID-19 vaccination in the dexamethasone group was lower than that in the nondexamethasone group with a statistically significant difference (47.22 v 141.09 U/mL, P = .035). The anti–S IgG seroconversion rate was also significantly lower in the dexamethasone group than in the nondexamethasone group (93.83% v 80.95%, P = .023). The lowest median anti–SARS-CoV-2 IgG titer level at 7.89 AU/mL was observed in patients with the highest dose of steroid group (≥37 mg of dexamethasone cumulative dose throughout the course of chemotherapy [per course]) and patients who were injected with COVID-19 vaccines on the same day of receiving dexamethasone, 25.41 AU/mL. CONCLUSION: Patients with solid cancer vaccinated against COVID-19 disease while receiving dexamethasone had lower immunogenicity responses than those who got vaccines without dexamethasone. The direct association between the immunogenicity level and steroid dosage, as well as length of duration from vaccination to dexamethasone, was observed.


  • Open Access

    Comparative Diagnostic Accuracy of Self-Administered and Professional Antigen-detecting Rapid Diagnostics Tests for SARS-CoV-2 Infection in Individuals with or without Symptoms.

    by Bhawarankorn Vanichsetakul, Teerawich Oonsaengchan, Wasanai Krisorakun, Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Gaidganok Sornsamdang, Naroedee Liwruengkul, Kriangkrai Tawinprai

    Limited data exist comparing the diagnostic performance of antigen-detecting rapid diagnostic tests (Ag-RDTs) when collected by healthcare personnel versus self-collection. This single-center study, conducted from October 2021 to January 2022, involved 245 symptomatic and 203 high-risk participants aged above 18. Randomization determined the utilization of two Ag-RDT types: 5T for self-testing and 25T administered by medical professionals. Of the participants, 78 individuals tested positive via RT-PCR, with 67 in the symptomatic group and 11 in the high-risk group. Notably, Ag-RDT displayed excellent performance, achieving an AuROC of 0.93 (95%CI, 0.90–0.97). No significant difference in accuracy between the two Ag-RDT types was found, with AuROC values of 0.92 for self-test and 0.94 for professional test Ag-RDT (p-value = 0.564). Within the symptomatic group, there was a sensitivity of 88.1% (95%CI, 77.8–94.7) and a specificity of 99.3% (95%CI, 96.3–100). In the high-risk group, Ag-RDT showed a sensitivity of 81.8% (95%CI, 48.2–97.7) and a specificity of 100% (95%CI, 98.0–100). This study highlights the equal accuracy of self-administered and professionally conducted Ag-RDT tests for SARS-CoV-2 detection.

  • Open Access

    The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study

    by Thachanun Porntharukchareon, Wipada Chartisathian, Manassamon Navinpipat, Chayanee Samdaengpan, Kunsuda Cheirsilpa, Aimwipa Lueprasitsakul, Supanat Worawichawong, Viroj Muangsillapasart, Pratya Pumuthaivirat, Bothamai Dechates, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) increases mortality rates in older adults and those with comorbidities. Individuals with certain comorbidities may have a poor immune response and require early booster vaccines. We aimed to assess the immune response after two doses of ChAdOx1 nCoV-19 vaccine, at 84-day intervals, in participants with the following comorbidities; diabetes mellitus; obesity; cardiovascular disease; chronic kidney disease; rheumatological disease; cirrhosis; hematological disease; hematological malignancy; or solid malignancy. The study was conducted at Chulabhorn Hospital in Thailand, with healthy healthcare workers serving as the control group. Of the 769 participants, 352 were in the healthy cohort and 417 were in the comorbidity cohort, all received at least one dose of vaccine. Anti-RBD total antibody levels were evaluated on Day 0, Day 84, and Day 112. The results at Day 112 (4 weeks after the second dose) showed that individuals with comorbidities had a poor immune response compared to healthy individuals, especially those with hematological malignancy and solid malignancy. The geometric mean concentration (GMC) of anti-RBD antibody in the comorbidity cohort was significantly lower than that in the healthy cohort: 433.66 BAU/ml (95% CI 334.62–562.01) versus 1096.14 BAU/ml (95% CI 1010.26–1189.33), respectively. The geometric mean ratio (GMR) between the two cohorts was 0.40 (95% CI 0.30–0.52, p < .001). This study concluded that individuals with comorbidities, particularly hematological and solid malignancies, had poor immune responses and may require an early booster vaccine to prevent infection and death.


  • Open Access

    The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study

    by Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Kunsuda Cheirsilpa, Teerapat Ungtrakul, Wasanai Krisorakun, Chanisa Chotipanich, Nat Wimolsiri, Permpen Noitun, Netnapis Srirattana, Nithi Mahanonda

    Background: Favipiravir has complex pharmacokinetics, and varied efficacy has been reported in treating COVID-19. Telehealth and telemonitoring are disruptive challenges used for COVID-19 care during pandemics. Objective: This study aimed to assess the outcome of favipiravir treatment to prevent clinical deterioration in mild to moderate COVID-19 cases with adjunctive telemonitoring during the COVID-19 surge. Methods: This was a retrospective observational study of PCR-confirmed mild to moderate COVID-19 cases subjected to home isolation. Chest computed tomography (CT) was performed in all cases, and favipiravir was administrated. Results: This study involved 88 PCR-confirmed COVID-19 cases. In addition, 42/42 (100%) cases were Alpha variants. COVID-19 pneumonia was found in 71.5% of the cases, according to chest X-rays and chest CT on the first visit. Favipiravir started 4 days after symptoms, which was part of the standard of care. The 12.5% of the patients required supplemental oxygen and intensive care unit admission rate was 1.1%; 1.1% required mechanical ventilation, and the rate of all-cause mortality was 1.1%, with a value of 0% of severe COVID-19 deaths. All mild illness cases showed no clinical deterioration or requirement for supplemental oxygen. No significant deterioration in either obesity or diabetes mellitus was observed. Conclusions: Favipiravir treatment for mild to moderate COVID-19 cases in outpatient settings, coupled with telemonitoring, was both safe and effective in preventing clinical deterioration, including the need for oxygen supplementation. This approach proved valuable during surges of COVID-19 cases.


  • Open Access

    Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers

    by Bothamai Dechates, Thachanun Porntharukchareon, Supamas Sirisreetreerux, Phonthip Therawit, Supanat Worawitchawong, Gaidganok Sornsamdang, Kamonwan Soonklang, Kriangkrai Tawinprai

    Background: Vaccines for SARS-CoV-2 have been critical for preventing disease. Previous research showed patients with diabetes have impaired immunity. This study aimed to determine the immunity to coronavirus after CoronaVac by comparing patients with type 2 diabetes (T2D) and healthcare workers (HCW). Materials and methods: A prospective cohort study evaluated immune responses and safety after two doses of CoronaVac in T2D and HCW groups at Chulabhorn Hospital. The levels of total antibodies against the receptor-binding domain (anti-RBD) of the SARS-CoV-2 spike protein at baseline and 4 weeks after vaccination were collected. The level of anti-RBD concentrations was reported as geometric mean concentration (GMC) and compared between groups using the geometric mean ratio (GMR). Results: 81 participants were included; 27 had T2D and 54 were HCW. After complete vaccination, anti-RBD concentrations were not significantly different between T2D (57.68 binding antibody units (BAU)/mL, 95% confidence interval (CI) = 29.08; 114.44) and HCW (72.49 BAU/mL, 95% CI = 55.77; 94.22) groups. Subgroup analysis showed the GMC of anti-RBD was significantly lower in T2D patients with dyslipidaemia (50.04 BAU/mL) than in T2D patients without dyslipidaemia (341.64 BAU/mL). Conclusions: The immune response at 4 weeks after two doses of CoronaVac did not significantly differ between patients with T2D and HCW.


  • Open Access

    Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment

    by Walaipan Tantiyavarong, Prakongboon Sungkasubun, Worawit Chaiwiriyawong, Archara Supavavej, Piyarat Limpawittayakul, Bowon Weerasubpong, Jomtana Siripaibun, Chumut Phanthunane, Wisut Lamlertthon, Teerapat Ungtrakul, et al.

    PURPOSE: The COVID-19 pandemic has affected public health worldwide. The efficacy and safety of COVID-19 vaccines have been evaluated in the general population; however, data on patients with malignancies are limited. METHODS: This prospective longitudinal observational cohort study was conducted between June and July 2021. Enrolled adult patients with cancer were divided into chemotherapy and nonchemotherapy groups. All participants were immunized with two doses of the ChAdOx1 nCoV-19 or CoronaVac COVID-19 vaccines. The primary outcome was a comparison of the immunogenicity (as assessed by spike protein [anti-S] immunoglobulin G [IgG] antibody titers) of two doses of COVID-19 vaccine in the chemotherapy and nonchemotherapy groups. The secondary outcomes included the anti-S IgG seroconversion rate and vaccine safety in both groups. RESULTS: Among the 173 enrolled patients with solid cancer, after COVID-19 vaccination, the chemotherapy group had a significantly lower median anti-S IgG titer than the nonchemotherapy group (26 v 237 U/mL, P < .001). A statistically significant difference in anti-S IgG titer was found between groups vaccinated with CoronaVac (7 v 90 U/mL, P < .001), but no difference was found in those vaccinated with ChAdOx1 nCoV-19 (818 v 1061 U/mL, P = .075). The anti-S IgG seroconversion rate was significantly lower in the chemotherapy group than that in the nonchemotherapy group (78.9% v 96.5%, P = .001). No new or serious vaccine-related adverse events were reported. CONCLUSION: Patients with solid cancer receiving a COVID-19 vaccine while undergoing chemotherapy had lower immunogenicity responses to vaccination than those who were vaccinated while undergoing nonchemotherapy treatment. No statistically significant difference was observed in the COVID-19 vaccine safety profiles between groups.


  • Open Access

    Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

    by Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul

    The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune response. We aimed to compare the immunogenicity and safety of a heterologous prime-boost vaccination using an inactivated COVID-19 vaccine and AZD1222 vaccine with that of a homologous vaccination using AZD1222. This pilot involved 164 healthy volunteers without prior SARS-CoV-2 infection aged 18 years or older assigned to receive either the heterologous or homologous vaccination. The results showed that the heterologous approach was safe and well-tolerated, although the reactogenicity of the heterologous approach was higher. At 4 weeks after receiving the booster dose, the heterologous approach elicited a non-inferior immune response compared to the homologous approach in neutralizing antibody and cell-mediated immune response. The percentage of inhibition was 83.88 (79.72–88.03) in the heterologous and 79.88 (75.50–84.25) in the homologous group, a mean difference of 4.60 (−1.67–10.88). The geometric mean of interferon-gamma was 1072.53 mIU/mL (799.29–1439.18) in the heterologous group and 867.67 mIU/mL (671.94–1120.40) in the homologous group, a GMR of 1.24 (0.82–1.85). However, the binding antibody test of the heterologous group was inferior to the homologous group. Our findings suggest that the use of heterologous prime-boost vaccination with different types of COVID-19 vaccines is a viable strategy, especially in settings where vaccine supply is limited or where vaccine distribution is challenging.


  • Open Access

    Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies

    by Chayapa Thookhamme, Manassamon Navinpipat, Aimwipa Sasakul, Pakthipa Pattarakosol, Kamoltip Lertchaisataporn, Kriangkrai Tawinprai, Pannee Praditsuktavorn

    Thookhamme C, et al. Clin Exp Vaccine Res. 2023 Apr;12(2):107-115. https://doi.org/10.7774/cevr.2023.12.2.107

  • Open Access

    Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

    by Saraiorn Thonginnetra, Kriangkrai Tawinprai, Krongkwan Niemsorn, Pathariya Promsena, Manunya Tandhansakul, Naruporn Kasemlawan, Natthanan Ruangkijpaisal, Narin Banomyong, Nanthida Phattraprayoon, Pisuttikan Rangkakulnuwat, et al.

    Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2–7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2–7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine’s safety profile in this age group.


  • Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine

    by Kriangkrai Tawinprai, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Gaidganok Sornsamdang, Chirayu Auewarakul, Nithi Mahanonda

    Immunogenicity after the CoronaVac vaccine remains uncertain, especially regarding infections with the coronavirus variants of concern and waning immunity.This was a single-center, open-label clini...